Trials / Completed
CompletedNCT00034463
ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer
A Phase 1 Trial of ALIMTA (Pemetrexed) in Patients With Locally Advanced or Metastatic Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- —
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is a non-randomized, phase 1, study with the primary objective of determining the toxicities and establishing the maximum tolerated dose of ALIMTA when administered as a 10 minute infusion every 21 days with folic acid or multi-vitamin supplementation therapy in lightly or heavily pre-treated patients with locally advanced or metastatic cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ALIMTA | |
| DRUG | folic acid | |
| DRUG | multi-vitamins |
Timeline
- First posted
- 2002-04-30
- Last updated
- 2006-07-19
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT00034463. Inclusion in this directory is not an endorsement.